The Endometriosis market size is estimated to be $1.9Bn, in 2018, growing at a CAGR of 2.9% during 2019-2024. Increase focus on woman health and easy availability of patient assistance program are some of the key factors driving the endometriosis market over the forecast period, 2019 to 2024. Women with endometriosis could also have endometrial cyst which is also known as ovarian cyst. This could lead to other complications like causing chronic pelvic pain and raise the overall risk for ovarian cancer. Laparoscopy is one of the most definitive ways to do endometriosis diagnosis. The disease is often misdiagnosed with fibroid tumors and adenomyosis.
- The ultrasound segment held the largest market share in terms of revenue with 31.01%, in 2018.
- North America held the largest market share with 51.61%.
By Diagnosis Type - Segment Analysis
The endometriosis market by diagnosis type has been segmented into ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy and sonohysterography. The ultrasound segment held the largest market share in terms of revenue with 31.01%, in 2018. Rising demand for minimal invasive and non-invasive diagnostic procedures coupled with innovation in technology is a key factor resulting in the revenue share. Hysteroscopy followed ultrasound segment in terms of revenue in the same year. Laparoscopy is expected to grow the fastest over the forecast period, 2019 to 2024.
Geography - Segment Analysis
The Endometriosis market by geography has been segmented into North America, South America, Europe, Asia Pacific and Rest of the World. North America held the largest endometriosis market share of 51.61% revenue wise, in 2018. The high prevalence of endometriosis in North America is driving market growth in the region. The high incidence rate of the disease has led to the growth in sales of hormone therapeutics to treat the condition. Vendors are also focusing on developing active hormone treatments to overcome challenges, which involves various side-effects, linked with the available medications in the market. Europe followed North America in terms of revenue share in the same year. Further, Asia Pacific is expected to grow the fastest over the forecast period, 2019 to 2024.
- Growing prevalence of endometriosis
The growing prevalence of endometriosis has led to higher awareness among the patients regarding the endometriosis treatment. Further, there is rise in focus in research and development with the increase occurrence of the disease. Moreover, government agencies are investing in healthcare infrastructure to provide better treatment facility to the patients. Thus more drugs and diagnosis equipment in line with the treatment of endometriosis are required thus driving the market further.
- Availability of patient assistance programs
The market is controlled by high-cost hormone-based therapeutics, which plays a significant role in the treatment of endometriosis of the patient. Thus, companies such as Bayer and AbbVie are providing patient-assistance programs which helps to reduce the cost burden on the patients. The accessibility of patient assistance programs for expensive drugs is expected to rise patient adherence to such drugs medications, which will in turn drive the market over the forecast period.
- Lack of non-invasive diagnostics
The absence of non-invasive diagnostics tests which are available in the market for endometriosis is a key factor restraining the market over the forecast period. Most people are scared, and try to avoid the pain associated with the non-invasive diagnostics procedure. However, more and more woman are being aware of the early detection of endometriosis and are non-hesitant to go forward with such diagnostics.
Merger, acquisition, partnership, product innovation and focus in research and development are some of the key strategies adopted by players operating in the endometriosis market. In 2018, the market for endometriosis was fragmented with the top ten players accounting for 22.18% of the global market share. Endometriosis top 10 companies are AbbVie Inc., Abbott, Ipsen, Bayer AG, Myovant Sciences Ltd., Philogen, Pfizer, Inc., Astellas Pharma, Orphagen Pharmaceuticals, Inc. and Meditrina Pharmaceuticals.
- On March 2018, Astellas Pharma announced the development of Opigolix (ASP 1707), a luteinizing-hormone-releasing hormone receptor antagonist. The product can be used for the oral treatment of endometriosis. This product is expected to give competitive advantage to the company over other companies which are operating in the same line of business.